Bristol-Myers Squibb (NY:BMY)

Pharmaceutical Stocks Soar as White House Unveils Drug-Pricing Agreement, AbbVie Leads the Charge

September 30, 2025

Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing...

Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026 ↗

September 25, 2025

Bristol Myers Announces Positive Outcomes From Multiple Myeloma Late-Stage Study ↗

September 23, 2025

But Trump might get less than he bargained for as drugmakers focus on prices abroad, rather than stateside efforts.

Trump's Plan To Lower U.S. Drug Prices Faces Big Test ↗

September 30, 2025

Via Investor's Business Daily

Topics Government

Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes

September 29, 2025

Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by...

Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Program ↗

September 29, 2025

The announcement from the group coincides with the deadline set by President Trump for 17 pharmaceutical companies to reduce drug prices in the U.S. to the levels paid by other developed countries.

J&J’s Investigational Plaque Psoriasis Drug Outperforms Bristol Myers’ Sotyktu In Study ↗

Topics Government

September 17, 2025

In a hypothetical scenario playing out just last week, leading up to September 27, 2025, Johnson & Johnson (NYSE: JNJ) experienced a significant stock rally, capturing the attention of investors and...

Johnson & Johnson's Hypothetical Rally: A Look at Potential 2025 Valuation Drivers

September 27, 2025

Immuneering Corporation's Stock Takes a Hit Amidst Funding Round Despite Promising Clinical Data

Topics Economy Intellectual Property

September 27, 2025

Boston, MA – September 27, 2025 – Immuneering Corporation (NASDAQ: IMRX) experienced a significant downturn in its stock value on September 25, 2025, with shares declining by approximately 13.3%. This...

Trump's 100% Drug Tariffs 'A Meaningful Commercial Hit' For Americans, But 'Loopholes' Could Blunt Impact, Says Analyst ↗

September 26, 2025

President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly...

Via Benzinga

Topics Government World Trade

Global Markets Brace for Impact as New U.S. Tariffs Escalate Trade Tensions Amidst Geopolitical Volatility

September 26, 2025

September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025....

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗

Topics Artificial Intelligence Economy Emissions

September 26, 2025

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Via Benzinga

Topics Government World Trade

Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)

September 25, 2025

Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option.

The Smartest Dividend Stock to Buy With $1,000 Right Now ↗

September 24, 2025

Pfizer has a huge yield right now, but it might make more sense for dividend investors to step down in yield to these two alternatives.

Topics Intellectual Property

Should You Forget Pfizer and Buy These Unstoppable Stocks Instead? ↗

September 24, 2025

Bristol Myers Squibb Franchise Gains Momentum With Phase 3 Results In Multiple Myeloma Patients ↗

Topics Intellectual Property

September 23, 2025

Bristol Myers Squibb reported positive Phase 3 results for iberdomide in multiple myeloma; analysts eye CELMoDs as key to future growth.

Via Benzinga

Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma

September 23, 2025

Find out why investors seeking passive income want shares of this dividend payer in their portfolio.

1 Reason to Buy Bristol Myers Squibb Stock ↗

September 23, 2025

Johnson & Johnson's Uninterrupted Dividend Growth: Innovation in Medicine and MedTech Drives Strong Q2 2025 Performance

Topics Intellectual Property

September 22, 2025

Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter...

Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era

Topics Artificial Intelligence Intellectual Property

September 19, 2025

Johnson & Johnson (NYSE: JNJ) is making significant waves in the pharmaceutical landscape, announcing a trio of pivotal developments that underscore its robust pipeline and strategic focus on unmet...

Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes

September 19, 2025

Eli Lilly and Company (NYSE: LLY) is making significant waves in the oncology landscape with a series of major announcements concerning two of its innovative cancer therapies: Olomorasib and Jaypirca...

Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025

September 19, 2025

The fate of a once-promising cancer treatment now looks uncertain at best.

Why Replimune Stock Plummeted by Almost 40% Today ↗

September 18, 2025

Global Cell Therapy Market Size Expected to Reach $44 Billion as Demand for Regenerative Medicine Rises

September 18, 2025

EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NASDAQ:CRSP),(NASDAQ:BNTX),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence

Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials ↗

September 17, 2025

Johnson & Johnson and Protagonist Therapeutics announced new data from their Phase 3 studies to treat severe plaque psoriasis.

Via Benzinga

Advancing Cancer Research Brings New Hope for Patients Worldwide

September 17, 2025

Via Investor Brand Network

Topics Artificial Intelligence Intellectual Property

Advancing Cancer Research Brings New Hope for Patients Worldwide

September 17, 2025

EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOVA),(NYSE:MRK),(NASDAQ:AZN),(NYSE:BMY) EQNX::TICKER_END

Via FinancialNewsMedia

Topics Artificial Intelligence Intellectual Property

Bristol Myers Squibb Announces Dividend

September 17, 2025